Company expects to end 2022 with over $120M in cash, cash equivalents, and short-term investments and at the top of its net product revenue guidance of $105M-$110M
Company to report Q4 and FY 2022 financial results on or about March 8, 2023
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that, in connection with investor meetings the Company is planning to conduct next week in San Francisco, it has updated its outlook for full year 2022 expecting net product revenue to be at the top of its guidance range of $105 million to $110 million and its year-end cash balance to be above the previously announced range of $110 million to $120 million.
"Our momentum continued through the fourth quarter with strong patient demand for both Recorlev® and Keveyis® and better than expected prescription growth for Gvoke® giving us confidence that we will end 2022 at the top of our net product revenue guidance of $105 million to $110 million," said Paul R. Edick, Xeris’ Chairman and CEO. "Also in the fourth quarter, we drew down the final $50 million tranche from our Hayfin debt facility, received an upfront payment from the Horizon Therapeutics collaboration and option agreement, and continued disciplined management of our cash and expenses and expect to end 2022 with over $120 million in cash, cash equivalents, and short-term investments."
https://finance.yahoo.com/news/xeris-biopharma-updates-outlook-2022-120000703.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.